89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.
- Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.
- “As 89bio executes on its ongoing Phase 3 programs for pegozafermin, this is an opportune time to add an industry leader like Martin to our board,” said Rohan Palekar, Chief Executive Officer of 89bio.
- Mr. Babler previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development.
- I am excited to work alongside the management team and Board of Directors to bring pegozafermin to the many patients in need.”